siRNA targeting mammalian target of rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy

Current Eye Research

Volumn 32, Issue 11, 2007, Pages 973-984

  Zhou, Peng ^a   Zhao, Ming Wei ^a   Li, Xiao Xin ^a   Yu, Wen Zhen ^a   Bian, Zong Mei ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Human retinal pigment epithelial cell; Mammalian target of rapamycin; Migration; Proliferative vitreoretinopathy; Small interfering RNA

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HUMAN; HUMAN CELL; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RETINA DETACHMENT; VITREORETINOPATHY;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE THERAPY; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HUMANS; PIGMENT EPITHELIUM OF EYE; PROTEIN KINASES; RABBITS; RETINAL DETACHMENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; VITREORETINOPATHY, PROLIFERATIVE;

EID: 36248957193     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701658323     Document Type: Article

References (22)

1. Campochiaro PA. Pathogenesis of proliferative vitreoretinopathy. In: Ogden DH, Schachat AP, Murphy RP, Glaser BM, Ryan SJ, eds. Retina. Vol. 3. London: C.V. Mosby; 2001:2221-2227.
2. Eibl KH, Kook D, Priglinger S, et al. Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by alkylphosphocholines. Investigative Ophthalmology & Visual Science. 2006;47:364-370.
3. Blankenship GW. Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefe's archive for clinical and experimental ophthalmology. 1989;227:565-568.
4. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1991;229:464-467.
5. Araiz JJ, Refojo MF, Arroyo MH, Leong FL, Albert DM, Tolentino FI. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Investigative Ophthalmology & Visual Science. 1993;34:522-530.
6. Lee JJ, Park JK, Kim YT, et al. Effect of 2′-benzoyl- oxycinnamaldehyde on RPE cells in vitro and in an experimental proliferative vitreoretinopathy model. Investigative Ophthalmology & Visual Science. 2002;43:3117-3124.
7. Eibl KH, Banas B, Schoenfeld CL, et al. Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells. Investigative Ophthalmology & Visual Science. 2003;44:3556-3561.
8. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chemical Biology. 2006;2:711-719.
9. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Current Cancer Drug Targets. 2004;4:621-635.
10. Rhoads JM, Niu X, Odle J, Graves LM. Role of mTOR signaling in intestinal cell migration. American Journal of Physiology. 2006;291:G510-517.
11. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Investigative Ophthalmology & Visual Science. 2005;46:454-460.
12. Zhang L, Li X, Zhao M, et al. Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: a key step in the progression of proliferative vitreoretinopathy. Experimental Eye Research. 2006;83:1405-1411.
13. Fastenberg DM, Diddie KR, Sorgente N, Ryan SJ. A comparison of different cellular inocula in an experimental model of massive periretinal proliferation. American Journal of Ophthalmology. 1982;93:559-564.
14. Davis AA, Bernstein PS, Bok D, Turner J, Nachtigal M, Hunt RC. A human retinal pigment epithelial cell line that retains epithelial characteristics after prolonged culture. Investigative Ophthalmology & Visual Science. 1995;36:955-964.
15. Kristof AS, Marks-Konczalik J, Billings E, Moss J. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. The Journal of Biological Chemistry. 2003;278:33637-33644.
16. Hsieh AC, Bo R, Manola J, et al. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Research. 2004;32:893-901.
17. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. The Journal of Biological Chemistry. 2004;279:23166-23175.
18. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91:12574-12578.
19. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treatment Reviews. 2007;33:78-84.
20. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Research. 1999;59:886-894.
21. Jin M, He S, Worpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-alpha. Investigative Ophthalmology & Visual Science. 2000;41:4324-4332.
22. Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF recep tor 1. Gene Therapy. 2006;13:225-234.